A notable jump in share price suggests potential growth for Appili Therapeutics.
Appili Therapeutics Inc experienced a significant rise in its stock price yesterday, increasing by 50%. This surge indicates strong investor interest and optimism about the company’s future.
Advertisement
Appili Therapeutics Inc
APLI.TO
APLI.TO
Appili Therapeutics Inc
WealthAwesomeMarket cap
$1.32M
52W high
$0.04
52W low
$0.01
1W change
+0.00%
Beta
-0.19
Analyst Price Targets
Based on analyst covering APLI · as of Sep 17, 2026
Wall Street analysts forecast APLI stock price to rise 1400.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.15
+1400.0% Upside
Current Price
C$0.01
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APLI's historical volatility
30-Day Vol
414.0%
Annualized
90-Day Vol
295.4%
Annualized
Trend (90d)
+0.0%
Annualized drift
90d Mean
C$0.02
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.02 | C$0.00 – C$0.06 |
| 60 trading days | C$0.02 | C$0.00 – C$0.11 |
| 90 trading days | C$0.02 | C$0.00 – C$0.18 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: While this increase shows strong market interest, investors should stay cautious and consider the company's overall financial health and operational developments.
50% Surge in Stock Price
Appili Therapeutics Inc's stock price climbed to CA$0.01, a notable rise that could attract both new and existing investors.
Bull case
The recent 50% increase in stock price likely reflects positive investor sentiment towards Appili's ongoing projects and the potential revenue from products like LIKMEZ®.
Bear case
Despite the impressive rise, the company is still operating at a loss, with a profit margin of 0%. This raises concerns about its long-term sustainability and profitability.
Understanding the Surge
Advertisement
The 50% surge in Appili Therapeutics' stock price can be linked to increased investor interest, possibly fueled by recent operational updates and ongoing projects. Investors may be hopeful about the commercial prospects of LIKMEZ® in the U.S. market, which could lead to future revenue growth.
Financial Health Concerns
Even with the recent stock price increase, Appili Therapeutics faces challenges due to a profit margin of 0% and ongoing financial losses. Investors should carefully assess these factors alongside the recent surge. For more details on the company's financial performance, check out our analysis on APLI.TO.
Future Outlook
Looking ahead, Appili's ability to keep investor interest will hinge on its operational success and financial stability. The recent surge may draw attention, but potential investors should remain aware of the risks involved. For ongoing updates and insights about Appili Therapeutics, visit our stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
